234 related articles for article (PubMed ID: 38673793)
1. Transitioning to a Personalized Approach in Molecularly Subtyped Small-Cell Lung Cancer (SCLC).
Grenda A; Krawczyk P; Obara A; Gajek Ł; Łomża-Łaba A; Milanowski J
Int J Mol Sci; 2024 Apr; 25(8):. PubMed ID: 38673793
[TBL] [Abstract][Full Text] [Related]
2. Prospects of targeted and immune therapies in SCLC.
Hendriks LEL; Menis J; Reck M
Expert Rev Anticancer Ther; 2019 Feb; 19(2):151-167. PubMed ID: 30590971
[No Abstract] [Full Text] [Related]
3. Development of molecularly targeted agents and immunotherapies in small cell lung cancer.
Sharp A; Bhosle J; Abdelraouf F; Popat S; O'Brien M; Yap TA
Eur J Cancer; 2016 Jun; 60():26-39. PubMed ID: 27060747
[TBL] [Abstract][Full Text] [Related]
4. Systemic Therapy of Extensive Stage Small Cell Lung Cancer in the Era of Immunotherapy.
Ragavan M; Das M
Curr Treat Options Oncol; 2020 Jun; 21(8):64. PubMed ID: 32601742
[TBL] [Abstract][Full Text] [Related]
5. SCLC-State of the Art and What Does the Future Have in Store?
Kahnert K; Kauffmann-Guerrero D; Huber RM
Clin Lung Cancer; 2016 Sep; 17(5):325-333. PubMed ID: 27397481
[TBL] [Abstract][Full Text] [Related]
6. What Are the Biomarkers for Immunotherapy in SCLC?
Longo V; Catino A; Montrone M; Pizzutilo P; Annese T; Pesola F; Marech I; Cassiano S; Ribatti D; Galetta D
Int J Mol Sci; 2021 Oct; 22(20):. PubMed ID: 34681779
[TBL] [Abstract][Full Text] [Related]
7. Unravelling the biology of SCLC: implications for therapy.
Sabari JK; Lok BH; Laird JH; Poirier JT; Rudin CM
Nat Rev Clin Oncol; 2017 Sep; 14(9):549-561. PubMed ID: 28534531
[TBL] [Abstract][Full Text] [Related]
8. Targeted Therapy and Immune Therapy for Small Cell Lung Cancer.
Gadgeel SM
Curr Treat Options Oncol; 2018 Sep; 19(11):53. PubMed ID: 30203184
[TBL] [Abstract][Full Text] [Related]
9. DLL3-guided therapies in small-cell lung cancer: from antibody-drug conjugate to precision immunotherapy and radioimmunotherapy.
Su PL; Chakravarthy K; Furuya N; Brownstein J; Yu J; Long M; Carbone D; Li Z; He K
Mol Cancer; 2024 May; 23(1):97. PubMed ID: 38730427
[TBL] [Abstract][Full Text] [Related]
10. New Therapies and Biomarkers: Are We Ready for Personalized Treatment in Small Cell Lung Cancer?
Zhang B; Birer SR; Dvorkin M; Shruti J; Byers L
Am Soc Clin Oncol Educ Book; 2021 Mar; 41():1-10. PubMed ID: 33979194
[TBL] [Abstract][Full Text] [Related]
11. Extensive-stage small-cell lung cancer: Current management and future directions.
Yu Y; Chen K; Fan Y
Int J Cancer; 2023 Jun; 152(11):2243-2256. PubMed ID: 36346100
[TBL] [Abstract][Full Text] [Related]
12. Molecular subtyping of small-cell lung cancer based on mutational signatures with different genomic features and therapeutic strategies.
Wang H; Wu S; Li Z; Zhang C; Shang X; Zhao C; Li Z; Lin J; Guo J; Wang Z
Cancer Sci; 2023 Feb; 114(2):665-679. PubMed ID: 36178064
[TBL] [Abstract][Full Text] [Related]
13. Targeted therapies for small cell lung cancer: Where do we stand?
Arcaro A
Crit Rev Oncol Hematol; 2015 Aug; 95(2):154-64. PubMed ID: 25800975
[TBL] [Abstract][Full Text] [Related]
14. Development of targeted therapy and immunotherapy for treatment of small cell lung cancer.
Saito M; Shiraishi K; Goto A; Suzuki H; Kohno T; Kono K
Jpn J Clin Oncol; 2018 Jul; 48(7):603-608. PubMed ID: 29762727
[TBL] [Abstract][Full Text] [Related]
15. Challenging the recalcitrant disease-developing molecularly driven treatments for small cell lung cancer.
Mak DWS; Li S; Minchom A
Eur J Cancer; 2019 Sep; 119():132-150. PubMed ID: 31445197
[TBL] [Abstract][Full Text] [Related]
16. Novel therapeutic combinations with PARP inhibitors for small cell lung cancer: A bench-to-bedside review.
Xiong J; Barayan R; Louie AV; Lok BH
Semin Cancer Biol; 2022 Nov; 86(Pt 2):521-542. PubMed ID: 35917883
[TBL] [Abstract][Full Text] [Related]
17. Personalized Therapy of Small Cell Lung Cancer.
Schneider BJ; Kalemkerian GP
Adv Exp Med Biol; 2016; 890():149-74. PubMed ID: 26703804
[TBL] [Abstract][Full Text] [Related]
18. Immunotherapy for small-cell lung cancer: emerging evidence.
Reck M; Heigener D; Reinmuth N
Future Oncol; 2016 Apr; 12(7):931-43. PubMed ID: 26882955
[TBL] [Abstract][Full Text] [Related]
19. Novel targeted strategies to overcome resistance in small-cell lung cancer: focus on PARP inhibitors and rovalpituzumab tesirine.
Van Den Borg R; Leonetti A; Tiseo M; Giovannetti E; Peters GJ
Expert Rev Anticancer Ther; 2019 Jun; 19(6):461-471. PubMed ID: 31148500
[No Abstract] [Full Text] [Related]
20. Origins, genetic landscape, and emerging therapies of small cell lung cancer.
Semenova EA; Nagel R; Berns A
Genes Dev; 2015 Jul; 29(14):1447-62. PubMed ID: 26220992
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
